<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:01:31Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9540525" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9540525</identifier>
        <datestamp>2022-10-14</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cncr34366" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cancer</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1097-0142</journal-id>
              <journal-id journal-id-type="publisher-id">CNCR</journal-id>
              <journal-title-group>
                <journal-title>Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0008-543X</issn>
              <issn pub-type="epub">1097-0142</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9540525</article-id>
              <article-id pub-id-type="pmcid">PMC9540525</article-id>
              <article-id pub-id-type="pmc-uid">9540525</article-id>
              <article-id pub-id-type="pmid">35737639</article-id>
              <article-id pub-id-type="pmid">35737639</article-id>
              <article-id pub-id-type="doi">10.1002/cncr.34366</article-id>
              <article-id pub-id-type="publisher-id">CNCR34366</article-id>
              <article-id pub-id-type="other">CNCR-22-0126.R1</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Discipline</subject>
                    <subj-group subj-group-type="heading">
                      <subject>Clinical Trials</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Clinical activity of <styled-content style="fixed-case" toggle="no">CC‐90011</styled-content>, an oral, potent, and reversible <styled-content style="fixed-case" toggle="no">LSD1</styled-content> inhibitor, in advanced malignancies</article-title>
              </title-group>
              <contrib-group>
                <contrib id="cncr34366-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Hollebecque</surname>
                    <given-names>Antoine</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2869-7551</contrib-id>
                  <xref rid="cncr34366-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>antoine.hollebecque@gustaveroussy.fr</email>
                  </address>
                </contrib>
                <contrib id="cncr34366-cr-0002" contrib-type="author">
                  <name>
                    <surname>Salvagni</surname>
                    <given-names>Stefania</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="cncr34366-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0003" contrib-type="author">
                  <name>
                    <surname>Plummer</surname>
                    <given-names>Ruth</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="cncr34366-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0004" contrib-type="author">
                  <name>
                    <surname>Niccoli</surname>
                    <given-names>Patricia</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="cncr34366-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0005" contrib-type="author">
                  <name>
                    <surname>Capdevila</surname>
                    <given-names>Jaume</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8017-9941</contrib-id>
                  <xref rid="cncr34366-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0006" contrib-type="author">
                  <name>
                    <surname>Curigliano</surname>
                    <given-names>Giuseppe</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1781-2518</contrib-id>
                  <xref rid="cncr34366-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0007" contrib-type="author">
                  <name>
                    <surname>Moreno</surname>
                    <given-names>Victor</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6099-4236</contrib-id>
                  <xref rid="cncr34366-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0008" contrib-type="author">
                  <name>
                    <surname>de Braud</surname>
                    <given-names>Filippo</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="cncr34366-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0009" contrib-type="author">
                  <name>
                    <surname>de Villambrosia</surname>
                    <given-names>Sonia Gonzalez</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="cncr34366-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0010" contrib-type="author">
                  <name>
                    <surname>Martin‐Romano</surname>
                    <given-names>Patricia</given-names>
                  </name>
                  <degrees>MD, MSc, PhD</degrees>
                  <xref rid="cncr34366-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0011" contrib-type="author">
                  <name>
                    <surname>Baudin</surname>
                    <given-names>Eric</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="cncr34366-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cncr34366-aff-0010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0012" contrib-type="author">
                  <name>
                    <surname>Arias</surname>
                    <given-names>Marina</given-names>
                  </name>
                  <degrees>MPharm</degrees>
                  <xref rid="cncr34366-aff-0011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0013" contrib-type="author">
                  <name>
                    <surname>de Alvaro</surname>
                    <given-names>Juan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="cncr34366-aff-0011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0014" contrib-type="author">
                  <name>
                    <surname>Parra‐Palau</surname>
                    <given-names>Josep L.</given-names>
                  </name>
                  <degrees>MSc, PhD</degrees>
                  <xref rid="cncr34366-aff-0011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0015" contrib-type="author">
                  <name>
                    <surname>Sánchez‐Pérez</surname>
                    <given-names>Tania</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="cncr34366-aff-0011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0016" contrib-type="author">
                  <name>
                    <surname>Aronchik</surname>
                    <given-names>Ida</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="cncr34366-aff-0012" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0017" contrib-type="author">
                  <name>
                    <surname>Filvaroff</surname>
                    <given-names>Ellen H.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="cncr34366-aff-0012" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0018" contrib-type="author">
                  <name>
                    <surname>Lamba</surname>
                    <given-names>Manisha</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="cncr34366-aff-0012" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0019" contrib-type="author">
                  <name>
                    <surname>Nikolova</surname>
                    <given-names>Zariana</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="cncr34366-aff-0011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib id="cncr34366-cr-0020" contrib-type="author">
                  <name>
                    <surname>de Bono</surname>
                    <given-names>Johann S.</given-names>
                  </name>
                  <degrees>MD, MSc, PhD, FRCP, FMedSci</degrees>
                  <xref rid="cncr34366-aff-0013" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="cncr34366-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Gustave Roussy</named-content>
                <institution>Département d'innovation thérapeutique et essais précoces</institution>
                <city>Villejuif</city>
                <country country="FR">France</country>
              </aff>
              <aff id="cncr34366-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">S. Orsola Polyclinic</named-content>
                <institution>Malpighi University Hospital</institution>
                <city>Bologna</city>
                <country country="IT">Italy</country>
              </aff>
              <aff id="cncr34366-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Clinical and Translational Research Institute Northern</named-content>
                <institution>Newcastle University</institution>
                <city>Newcastle</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="cncr34366-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medical Oncology</named-content>
                <named-content content-type="organisation-division">ENETS Center of Excellence</named-content>
                <institution>IPC NET Center</institution>
                <institution>Institut Paoli‐Calmettes</institution>
                <city>Marseille</city>
                <country country="FR">France</country>
              </aff>
              <aff id="cncr34366-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Vall d'Hebron Institute of Oncology</named-content>
                <institution>Vall d'Hebron University Hospital</institution>
                <named-content content-type="street">IOB‐Teknon</named-content>
                <city>Barcelona</city>
                <country country="ES">Spain</country>
              </aff>
              <aff id="cncr34366-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution>European Institute of Oncology, IRCCS, University of Milan</institution>
                <city>Milan</city>
                <country country="IT">Italy</country>
              </aff>
              <aff id="cncr34366-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">START Center for Cancer Care</named-content>
                <institution>Jimenez Diaz University Hospital</institution>
                <city>Madrid</city>
                <country country="ES">Spain</country>
              </aff>
              <aff id="cncr34366-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <institution>National Cancer Institute</institution>
                <city>Milan</city>
                <country country="IT">Italy</country>
              </aff>
              <aff id="cncr34366-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Department of Hematology</named-content>
                <institution>Hospital Universitario Marqués de Valdecilla/IDIVAL</institution>
                <city>Santander</city>
                <country country="ES">Spain</country>
              </aff>
              <aff id="cncr34366-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <named-content content-type="organisation-division">Gustave Roussy</named-content>
                <institution>Département D'oncologie Endocrinienne</institution>
                <city>Villejuif</city>
                <country country="FR">France</country>
              </aff>
              <aff id="cncr34366-aff-0011">
                <label>
                  <sup>11</sup>
                </label>
                <named-content content-type="organisation-division">Center for Innovation and Translational Research Europe</named-content>
                <institution>A Bristol Myers Squibb Company</institution>
                <city>Seville</city>
                <country country="ES">Spain</country>
              </aff>
              <aff id="cncr34366-aff-0012">
                <label>
                  <sup>12</sup>
                </label>
                <institution>Bristol Myers Squibb</institution>
                <city>Princeton</city>
                <named-content content-type="country-part">New Jersey</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cncr34366-aff-0013">
                <label>
                  <sup>13</sup>
                </label>
                <institution>The Institute of Cancer Research and Royal Marsden Hospital</institution>
                <city>London</city>
                <country country="GB">UK</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Corresponding Author:</bold> Antoine Hollebecque, Gustave Roussy, Département d'innovation thérapeutique et essais précoces, 114 Rue Edouard Vaillant, 94805 Villejuif, France (<email>antoine.hollebecque@gustaveroussy.fr</email>).</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>23</day>
                <month>6</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>01</day>
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <volume>128</volume>
              <issue seq="100">17</issue>
              <issue-id pub-id-type="doi">10.1002/cncr.v128.17</issue-id>
              <fpage>3185</fpage>
              <lpage>3195</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>05</day>
                  <month>5</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>18</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>19</day>
                  <month>5</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2022 American Cancer Society-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Cancer</italic> published by Wiley Periodicals LLC on behalf of American Cancer Society.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CNCR-128-3185.pdf"/>
              <abstract>
                <sec id="cncr34366-sec-0001">
                  <title>Background</title>
                  <p>CC‐90011 is an oral, potent, selective, reversible inhibitor of lysine‐specific demethylase 1 (LSD1) that was well tolerated, with encouraging activity in patients who had advanced solid tumors or relapsed/refractory marginal zone lymphoma. The authors present long‐term safety and efficacy and novel pharmacodynamic and pharmacokinetic data from the first‐in‐human study of CC‐90011.</p>
                </sec>
                <sec id="cncr34366-sec-0002">
                  <title>Methods</title>
                  <p>CC‐90011‐ST‐001 (<ext-link xlink:href="http://clincaltrials.gov" ext-link-type="uri">ClincalTrials.gov</ext-link> identifier NCT02875223; Eudract number 2015–005243‐13) is a phase 1, multicenter study in which patients received CC‐90011 once per week in 28‐day cycles. The objectives were to determine the safety, maximum tolerated dose, and/or recommended phase 2 dose (primary) and to evaluate preliminary efficacy and pharmacokinetics (secondary).</p>
                </sec>
                <sec id="cncr34366-sec-0003">
                  <title>Results</title>
                  <p>Sixty‐nine patients were enrolled, including 50 in the dose‐escalation arm and 19 in the dose‐expansion arm. Thrombocytopenia was the most common treatment‐related adverse event and was successfully managed with dose modifications. Clinical activity with prolonged, durable responses were observed, particularly in patients who had neuroendocrine neoplasms. In the dose‐escalation arm, one patient with relapsed/refractory marginal zone lymphoma achieved a complete response (ongoing in cycle 58). In the dose‐expansion arm, three patients with neuroendocrine neoplasms had stable disease after nine or more cycles, including one patient who was in cycle 46 of ongoing treatment. CC‐90011 decreased levels of secreted neuroendocrine peptides chromogranin A, progastrin‐releasing peptide, and RNA expression of the blood pharmacodynamic marker <italic toggle="no">monocyte‐to‐macrophage differentiation–associated</italic>.</p>
                </sec>
                <sec id="cncr34366-sec-0004">
                  <title>Conclusions</title>
                  <p>The safety profile of CC‐90011 suggested that its reversible mechanism of action may provide an advantage over other irreversible LSD1 inhibitors. The favorable tolerability profile, clinical activity, durable responses, and once‐per‐week dosing support further exploration of CC‐90011 as monotherapy and in combination with other treatments for patients with advanced solid tumors and other malignancies.</p>
                </sec>
              </abstract>
              <abstract abstract-type="short">
                <p>This first‐in‐human study evaluated CC‐90011, a highly potent, selective, and reversible oral lysine‐specific demethylase 1 inhibitor, in patients with advanced solid tumors and relapsed/refractory lymphoma. The tolerability, clinical activity, and once‐weekly dosing support further exploration of CC‐90011 in patients with advanced malignancies.</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="cncr34366-kwd-0001">CC‐90011</kwd>
                <kwd id="cncr34366-kwd-0002">epigenetic repression</kwd>
                <kwd id="cncr34366-kwd-0003">lysine‐specific demethylase 1 (LSD1) inhibitor</kwd>
                <kwd id="cncr34366-kwd-0004">neuroendocrine tumor</kwd>
                <kwd id="cncr34366-kwd-0005">non‐Hodgkin lymphoma</kwd>
                <kwd id="cncr34366-kwd-0006">pulrodemstat besilate</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Bristol Myers Squibb
</institution>
                      <institution-id institution-id-type="doi">10.13039/100008021</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="3"/>
                <page-count count="11"/>
                <word-count count="6983"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>September 1, 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.0 mode:remove_FC converted:07.10.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body id="cncr34366-body-0001">
            <sec id="cncr34366-sec-0005">
              <title>INTRODUCTION</title>
              <p>Lysine‐specific demethylase 1 (LSD1/KDM1A) is an epigenetic eraser that can modulate transcription through histone demethylation.<xref rid="cncr34366-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="cncr34366-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="cncr34366-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="cncr34366-bib-0004" ref-type="bibr"><sup>4</sup></xref> Histone demethylation by LSD1 plays an essential role in controlling wide‐ranging biologic processes, including the regulation of genes involved in pluripotency and lineage commitment in stem cells and during embryonic development.<xref rid="cncr34366-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cncr34366-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="cncr34366-bib-0006" ref-type="bibr"><sup>6</sup></xref> Overexpression of LSD1 may impede cell differentiation and contribute to metastasis and disease recurrence,<xref rid="cncr34366-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="cncr34366-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="cncr34366-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="cncr34366-bib-0010" ref-type="bibr"><sup>10</sup></xref> and its aberrant activity and/or expression plays a role in promoting cell proliferation, migration, and invasion in a variety of human cancers.<xref rid="cncr34366-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="cncr34366-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="cncr34366-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="cncr34366-bib-0012" ref-type="bibr"><sup>12</sup></xref> LSD1 dysregulation has been observed both in hematologic malignancies and in solid tumors,<xref rid="cncr34366-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="cncr34366-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="cncr34366-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="cncr34366-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="cncr34366-bib-0015" ref-type="bibr"><sup>15</sup></xref> including neuroendocrine neoplasms (NENs).<xref rid="cncr34366-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cncr34366-bib-0017" ref-type="bibr"><sup>17</sup></xref> LSD1 is expressed in &gt;25% of patients with mature B‐cell non‐Hodgkin lymphoma (NHL) and is in germinal centers.<xref rid="cncr34366-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="cncr34366-bib-0019" ref-type="bibr"><sup>19</sup></xref> Although aberrant expression is less common in low‐grade disease, a greater proportion of patients with high‐grade NHL express LSD1.<xref rid="cncr34366-bib-0018" ref-type="bibr"><sup>18</sup></xref> These findings highlight the therapeutic potential of LSD1 inhibitors for the treatment of oncologic malignancies.</p>
              <p>CC‐90011 is a potent, selective, and reversible oral LSD1 inhibitor<xref rid="cncr34366-bib-0020" ref-type="bibr"><sup>20</sup></xref> that has been shown to increase expression of tumor‐suppressing genes and decrease expression of tumor‐promoting genes, leading to decreased tumor cell growth.<xref rid="cncr34366-bib-0021" ref-type="bibr"><sup>21</sup></xref> CC‐90011 has demonstrated antiproliferative activity in cancer cell lines and in patient‐derived xenograft models.<xref rid="cncr34366-bib-0020" ref-type="bibr"><sup>20</sup></xref> CC‐90011 has antiproliferative activity in various solid tumor cell lines in vitro, including small cell lung cancer (SCLC; a type of NEN), and in acute myeloid leukemia cell lines.<xref rid="cncr34366-bib-0020" ref-type="bibr"><sup>20</sup></xref>
</p>
              <p>CC‐90011‐ST‐001 is a first‐in‐human dose‐escalation and dose‐expansion study. Primary results from this study demonstrated that CC‐90011 is well tolerated, with the recommended phase 2 dose (RP2D) established as 60 mg once per week. The maximum tolerated dose and nontolerated dose were determined to be 80 and 120 mg once per week, respectively. Notably, in the dose‐escalation arm of the study, a patient with relapsed/refractory (R/R) marginal zone lymphoma (MZL) achieved a durable complete response (CR) with CC‐90011 monotherapy, a patient with a solitary fibrous tumor achieved a partial response (PR), and seven patients with NENs had stable disease (SD) for ≥6 months, including bronchial neuroendocrine tumors, kidney tumors, and paraganglioma.</p>
              <p>Here, we report long‐term results from the dose‐escalation (with ≥60 months of follow‐up) and dose‐expansion arms of this study that included patients who had advanced NENs and R/R MZL. In addition, we provide further characterization of drug exposure through detailed pharmacokinetic and pharmacodynamic analyses.</p>
            </sec>
            <sec sec-type="materials-and-methods" id="cncr34366-sec-0006">
              <title>MATERIALS AND METHODS</title>
              <sec id="cncr34366-sec-0007">
                <title>Study design and patients</title>
                <p>CC‐90011‐ST‐001 (<ext-link xlink:href="http://clincaltrials.gov" ext-link-type="uri">ClincalTrials.gov</ext-link> identifier NCT02875223; Eudract number 2015–005243‐13) is a phase 1, open‐label, multicenter study of CC‐90011 for the treatment of patients with advanced or unresectable solid tumors, including NENs and R/R NHL. This study consists of two parts: a dose‐escalation arm, as reported previously,<xref rid="cncr34366-bib-0022" ref-type="bibr"><sup>22</sup></xref> and a dose‐expansion arm (see Figure S1). Results for dose expansion and long‐term follow‐up of dose escalation are reported here. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and in adherence to Good Clinical Practice as described in International Council for Harmonization Guideline E6. The protocol was reviewed and approved by each site's institutional review board or independent ethics committee before initiation of the study, and all patients provided written informed consent.</p>
                <p>Eligible patients for dose escalation have been previously described.<xref rid="cncr34366-bib-0022" ref-type="bibr"><sup>22</sup></xref> Patients who were eligible for dose expansion were aged 18 years or older who had histologic or cytologic confirmation of NENs or R/R NHL. Patients with NENs had low‐grade or intermediate‐grade lung NEN (including typical carcinoid and atypical carcinoid) or neuroendocrine prostate carcinoma (according to the World Health Organization classification). Patients with R/R NHL, including MZL, were those who progressed during or after standard anticancer therapy or for whom no other approved conventional therapy exists or is acceptable. Patients with solid tumors had to have at least one site of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Patients with R/R NHL had to have at least one site of measurable disease according to International Working Group criteria.<xref rid="cncr34366-bib-0023" ref-type="bibr"><sup>23</sup></xref> Additional inclusion criteria included an Eastern Cooperative Oncology Group performance status of 0 or 1 and adequate hematologic, hepatic, and renal function. Exclusion criteria for this study have been previously described.<xref rid="cncr34366-bib-0022" ref-type="bibr"><sup>22</sup></xref>
</p>
              </sec>
              <sec id="cncr34366-sec-0008">
                <title>Treatment</title>
                <p>In the dose‐expansion arm, CC‐90011 was administered orally once per week in each 28‐day cycle at a dose of 60 mg (the RP2D). The RP2D was selected based on the safety and preliminary efficacy results from the dose‐escalation arm of the study.<xref rid="cncr34366-bib-0022" ref-type="bibr"><sup>22</sup></xref> Dose reductions were permitted in any cycle, including cycle 1. Treatment could be interrupted up to 4 weeks until toxicity reached either grade ≤1 or baseline levels.</p>
              </sec>
              <sec id="cncr34366-sec-0009">
                <title>Study objectives</title>
                <p>The primary objectives were to determine the safety and tolerability of CC‐90011 and to define the maximum tolerated dose and the RP2D of CC‐90011 (dose escalation). Secondary objectives were to determine preliminary efficacy and to characterize the pharmacokinetics of CC‐90011. Exploratory objectives included evaluating the pharmacodynamic effects of CC‐90011 on gene expression and secreted neuropeptides. Study end points included preliminary efficacy (the clinical benefit rate [CBR], defined as response and SD rates according to disease‐appropriate response criteria; the overall response rate; the duration of response; and progression‐free survival [PFS]), overall survival (OS), pharmacokinetics (including the maximum observed plasma concentration, the area under the plasma concentration time‐curve [AUC], and the terminal half‐life), and pharmacodynamics (gene expression of monocyte‐to‐macrophage differentiation–associated [MMD] in peripheral blood and levels of the secreted neuropeptides progastrin‐releasing peptide [pro‐GRP] and chromogranin A [CgA]).</p>
              </sec>
              <sec id="cncr34366-sec-0010">
                <title>Efficacy and safety assessments</title>
                <p>Efficacy evaluations were performed after every two cycles through cycle six, and every three cycles thereafter. Patients who discontinued treatment for reasons other than disease progression, start of new anticancer therapy, or withdrawal of consent were followed until progression and/or initiation of new anticancer therapies. Tumor responses were determined by the investigator according to RECIST 1.1 for solid tumors and according to International Working Group criteria for NHL.<xref rid="cncr34366-bib-0024" ref-type="bibr"><sup>24</sup></xref> For neuroendocrine prostate carcinoma, response assessment was based on the Prostate Cancer Working Group 3 criteria.<xref rid="cncr34366-bib-0025" ref-type="bibr"><sup>25</sup></xref> [<sup>18</sup>F]‐fluorodeoxyglucose (FDG) positron emission tomography (PET) or FDG PET/computed tomography imaging was required to confirm a CR in patients who had FDG‐avid tumors. Adverse events (AEs) were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.</p>
              </sec>
              <sec id="cncr34366-sec-0011">
                <title>Pharmacokinetic and pharmacodynamic assessments</title>
                <p>Serial blood samples for pharmacokinetic analysis were collected ≤30 minutes before the dose on days 1, 8, 15, and 22 (predose) and days 1, 2, 4, 6, 8, 11, 24, and 48; and 72 and 96 hours postdose on days 1 and 22. Pharmacodynamic biomarkers of CC‐90011 (<italic toggle="yes">MMD</italic> gene expression and CgA and pro‐GRP soluble protein levels) were assessed ≤3 hours predose on days 1, 3, 5, 8, and 24 of cycle 1. MMD is a biomarker of CC‐90011 target engagement in the peripheral blood.<xref rid="cncr34366-bib-0026" ref-type="bibr"><sup>26</sup></xref> CgA and pro‐GRP are widely accepted biomarkers for assessing NENs and were previously established as downstream biomarkers of LSD1 inhibition.<xref rid="cncr34366-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="cncr34366-bib-0028" ref-type="bibr"><sup>28</sup></xref> Relative dose intensity was calculated as the actual dose intensity divided by the planned dose intensity.</p>
              </sec>
              <sec id="cncr34366-sec-0012">
                <title>Statistical analyses</title>
                <p>For dose expansion, sample sizes were not determined based on power calculation but, rather, on clinical, empirical, and practical considerations traditionally used for phase 1 studies. During dose expansion, at least 10–14 efficacy‐evaluable patients for each tumor cohort were initially accrued. The tumor cohort was expanded to approximately 10–20 patients if a response or SD lasting ≥4 months was observed. The treated population consisted of all patients who received at least one dose of CC‐90011. The efficacy‐evaluable population included patients who completed at least one treatment cycle and had a baseline and at least one valid postbaseline tumor assessments. Two‐sided 95% Clopper–Pearson exact confidence intervals (CIs) were determined for overall response rate and CBR estimates. All statistics were calculated based on observed values except for medians, which were calculated based on both observed and censored values using the Kaplan–Meier method. The pharmacokinetic‐evaluable population included patients who received at least one dose of CC‐90011 and had at least one measurement of CC‐90011 in blood. Plasma pharmacokinetic parameters were calculated using the noncompartmental analysis method from the plasma concentration‐time profiles of CC‐90011. Biomarker‐evaluable patients included those who received at least one dose of CC‐90011 and had at least one biomarker assessment. <italic toggle="yes">MMD</italic> expression levels in peripheral blood were normalized to the housekeeping gene <italic toggle="yes">PPIB</italic> and plotted as a percentage of cycle 1 day 1 (pretreatment baseline). Protein levels of CgA and pro‐GRP were assessed in serum. On‐treatment nadir levels and last assessment levels were plotted as a percentage of the pretreatment baseline; individual patient's neuropeptide nadirs were also plotted in relation to days on study. Study data were summarized for disposition, demographic and baseline characteristics, exposure, efficacy, safety, pharmacokinetics, and pharmacodynamics. Categorical data were summarized by frequency distributions (number and percentage of patients), and continuous data were summarized by descriptive statistics (means, standard deviation, median, minimum, and maximum). All statistical analyses were conducted using SAS version 9.3 or higher.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="cncr34366-sec-0013">
              <title>RESULTS</title>
              <sec id="cncr34366-sec-0014">
                <title>Patients and treatment</title>
                <p>As of the July 23, 2021, cutoff date, 69 patients who had solid tumors or R/R MZL were enrolled and treated, including 50 patients in the dose‐escalation arm and 19 in the dose‐expansion arm. In the dose‐expansion arm, 14 patients had bronchial NENs, two had prostate neuroendocrine carcinomas, and three had R/R MZL. Patient demographics and baseline characteristics are provided in Table <xref rid="cncr34366-tbl-0001" ref-type="table">1</xref>. In the dose‐expansion arm, the median patient age was 64 years (range, 36–81 years), and the median number of prior systemic anticancer therapies was two (range, from one to six therapies); 42% had received at least three prior therapies. As of the cutoff date, 17 patients (89%) had discontinued treatment, and two (11%) were still receiving study treatment. The reasons for treatment discontinuation were disease progression (<italic toggle="yes">n</italic> = 15; 79%) and death from disease progression (<italic toggle="yes">n</italic> = 2; 11%; see Table S1).</p>
                <table-wrap position="float" id="cncr34366-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Patient Baseline Characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="center" span="1"/>
                    <col align="center" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1"/>
                        <th colspan="2" style="border-bottom:solid 1px #000000" align="center" rowspan="1">No. (%)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Characteristic</th>
                        <th align="center" rowspan="1" colspan="1">Dose escalation, <italic toggle="yes">n</italic> = 50</th>
                        <th align="center" rowspan="1" colspan="1">Dose expansion, <italic toggle="yes">n</italic> = 19</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age: Median [range], years</td>
                        <td align="center" rowspan="1" colspan="1">61 [22–75]</td>
                        <td align="center" rowspan="1" colspan="1">64 [36–81]</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age ≥ 65 years</td>
                        <td align="center" rowspan="1" colspan="1">19 (38)</td>
                        <td align="center" rowspan="1" colspan="1">9 (47)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Men</td>
                        <td align="center" rowspan="1" colspan="1">26 (52)</td>
                        <td align="center" rowspan="1" colspan="1">11 (58)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ECOG PS</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">19 (38)</td>
                        <td align="center" rowspan="1" colspan="1">11 (58)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">1</td>
                        <td align="center" rowspan="1" colspan="1">31 (62)</td>
                        <td align="center" rowspan="1" colspan="1">8 (42)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Tumor type</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">NHL, MZL</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">3 (16)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Solid tumor</td>
                        <td align="center" rowspan="1" colspan="1">49 (98)</td>
                        <td align="center" rowspan="1" colspan="1">16 (84)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">NEN</td>
                        <td align="center" rowspan="1" colspan="1">27 (54)</td>
                        <td align="center" rowspan="1" colspan="1">16 (84)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Bronchial NET</td>
                        <td align="center" rowspan="1" colspan="1">4 (8)</td>
                        <td align="center" rowspan="1" colspan="1">14 (74)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Bronchial NEC</td>
                        <td align="center" rowspan="1" colspan="1">5 (10)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Prostate</td>
                        <td align="center" rowspan="1" colspan="1">5 (10)</td>
                        <td align="center" rowspan="1" colspan="1">2 (11)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">SCLC</td>
                        <td align="center" rowspan="1" colspan="1">2 (4)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Other<xref rid="cncr34366-note-0003" ref-type="table-fn">a</xref>
</td>
                        <td align="center" rowspan="1" colspan="1">11 (22)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Solid tumor stage IV<xref rid="cncr34366-note-0004" ref-type="table-fn">b</xref>
</td>
                        <td align="center" rowspan="1" colspan="1">43 of 49 (88)</td>
                        <td align="center" rowspan="1" colspan="1">16 of 16 (100)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">No. of prior systemic anticancer therapies: Median [range]</td>
                        <td align="center" rowspan="1" colspan="1">3 [1–9]</td>
                        <td align="center" rowspan="1" colspan="1">2 [1–6]</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">No. of prior systemic anticancer therapies</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" rowspan="1" colspan="1">1</td>
                        <td align="center" rowspan="1" colspan="1">2 (4)</td>
                        <td align="center" rowspan="1" colspan="1">6 (32)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" rowspan="1" colspan="1">2</td>
                        <td align="center" rowspan="1" colspan="1">17 (34)</td>
                        <td align="center" rowspan="1" colspan="1">4 (21)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" rowspan="1" colspan="1">≥3</td>
                        <td align="center" rowspan="1" colspan="1">29 (58)</td>
                        <td align="center" rowspan="1" colspan="1">8 (42)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cncr34366-ntgp-0001">
                    <fn id="cncr34366-note-0001">
                      <p><italic toggle="yes">Note:</italic> Data cutoff, July 23, 2021. Percentages may not total 100 because of rounding.</p>
                    </fn>
                    <fn id="cncr34366-note-0002">
                      <p>Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; MZL, marginal zone lymphoma; NEC, neuroendocrine carcinoma; NEN, neuroendocrine neoplasm; NET, neuroendocrine tumor; NHL, non‐Hodgkin lymphoma; SCLC, small‐cell lung cancer.</p>
                    </fn>
                    <fn id="cncr34366-note-0003">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Tumor types listed as other included cervical, urinary bladder, medullary thyroid cancer, and Merkel cell carcinoma.</p>
                    </fn>
                    <fn id="cncr34366-note-0004">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Ann Arbor stage I in the one patient with MZL in the dose‐escalation arm and stage IV in the three patients with MZL in the dose‐expansion arm.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Patients with NENs in the dose‐expansion arm received a median of 4.5 treatment cycles (range, 1–36 treatment cycles). The median duration of study treatment was 17.6 weeks (range, 4–142 weeks), and the mean relative dose intensity was 85% (range, 44%–108%). Five patients (31%) had at least one dose reduction because of AEs, and 13 patients (81%) had at least one dose interruption, 10 (63%) of which were because of AEs. The duration of interruption was &lt;3 days in seven patients (44%), 3–6 days in three patients (19%), and 7–14 days in three patients (19%; see Table S1). Among patients with R/R MZL, the median number of treatment cycles was one (range, from one to two cycles). The median duration of study treatment was 4.0 weeks (range, 3–5 weeks), and the mean relative dose intensity was 100%. None of the patients with R/R MZL had dose reductions. One patient in the MZL cohort had at least 1 dose interruption that was caused by AEs, with a duration less than 3 days.</p>
              </sec>
              <sec id="cncr34366-sec-0015">
                <title>Efficacy</title>
                <p>In the dose‐escalation arm, 1 patient with R/R MZL achieved a durable CR and was still ongoing treatment in cycle 58 as of April 2022 (Figure <xref rid="cncr34366-fig-0001" ref-type="fig">1A</xref>). A patient with a solitary fibrous tumor achieved a PR in cycle 36 of treatment, with an approximately 55% reduction in target lesion size by cycle 36 (Figure <xref rid="cncr34366-fig-0001" ref-type="fig">1B</xref>). That patient received 45 cycles of treatment before discontinuing treatment in March 2021. A reduction in target lesion size of up to approximately 30% was observed in six patients with a PFS &gt;9 months in both arms of the study (Figure <xref rid="cncr34366-fig-0001" ref-type="fig">1C</xref>). Among the 19 patients in the dose‐expansion arm, the CBR was 37% (95% CI, 16.3%–61.6%) (Table <xref rid="cncr34366-tbl-0002" ref-type="table">2</xref>). Ten patients (53%) had SD, and seven (37%) had SD of prolonged duration (≥4 months). Three patients with bronchial NENs had SD after nine or more cycles, with one patient still receiving treatment who had SD in cycle 46 as of April 2022. In the dose‐escalation and dose‐expansion arms, the median PFS was 3.4 months (95% CI, 1.7–3.7 months) and 1.8 months (95% CI, 1.1–5.4 months), respectively, and the median OS was 7.8 months (95% CI, 6.1–20.1 months) and 15.6 months (95% CI, 7.0, not estimable), respectively (Table <xref rid="cncr34366-tbl-0002" ref-type="table">2</xref>). Seven patients in the dose‐escalation arm who had grade ≥2 NENs and four who had NENs in the dose‐expansion arm had prolonged SD lasting &gt;6 months and PFS durations roughly twice as long as those achieved with their most recent prior therapy (see Figure S2).</p>
                <fig position="float" fig-type="Figure" id="cncr34366-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <p>(A) Time on treatment for 16 evaluable patients in the dose‐escalation arm and for all patients in the dose‐expansion arm. (B) Changes in tumor burden in response to CC‐90011 and the percentage change from baseline in tumor size over time are shown on computed tomography scans from a patient who had a solitary fibrous tumor. (C) Changes in patients with NENs/NETs and the percentage change from baseline in tumor size over time are shown in patients with NENs/NETs who had a progression‐free survival &gt;9 months, with each line representing an individual patient (data cutoff: January 6, 2022 for A; January 26, 2021, for B and C). CR indicates complete response; Gr, grade; LNEC, large cell neuroendocrine carcinoma; MZL, marginal zone lymphoma; NEC, neuroendocrine carcinoma; NENs, neuroendocrine neoplasms; NETs, neuroendocrine tumors; NHL, non‐Hodgkin lymphoma; PR, partial response; SD, stable disease.</p>
                  </caption>
                  <graphic xlink:href="CNCR-128-3185-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <table-wrap position="float" id="cncr34366-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Efficacy</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="center" span="1"/>
                    <col align="center" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Variable</th>
                        <th align="center" rowspan="1" colspan="1">Dose escalation, <italic toggle="yes">n</italic> = 50</th>
                        <th align="center" rowspan="1" colspan="1">Dose expansion, <italic toggle="yes">n</italic> = 19</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">CBR [95% CI], %</td>
                        <td align="center" rowspan="1" colspan="1">20 [10.0–33.7]</td>
                        <td align="center" rowspan="1" colspan="1">37 [16.3–61.6]</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ORR [95% CI], %</td>
                        <td align="center" rowspan="1" colspan="1">4 [0.5–13.7]</td>
                        <td align="center" rowspan="1" colspan="1">0 [0.0–17.6]</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Best overall response, no. (%)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">CR</td>
                        <td align="center" rowspan="1" colspan="1">1 (2.0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">PR</td>
                        <td align="center" rowspan="1" colspan="1">1 (2.0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">SD</td>
                        <td align="center" rowspan="1" colspan="1">22 (44.0)</td>
                        <td align="center" rowspan="1" colspan="1">10 (53.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" rowspan="1" colspan="1">SD ≥4 months</td>
                        <td align="center" rowspan="1" colspan="1">8 (16.0)</td>
                        <td align="center" rowspan="1" colspan="1">7 (37.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">PD</td>
                        <td align="center" rowspan="1" colspan="1">22 (44.0)</td>
                        <td align="center" rowspan="1" colspan="1">7 (37.0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">NE</td>
                        <td align="center" rowspan="1" colspan="1">4 (8.0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (11.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">mPFS [95% CI], months</td>
                        <td align="center" rowspan="1" colspan="1">3.4 [1.7–3.7]</td>
                        <td align="center" rowspan="1" colspan="1">1.8 [1.1–5.4]</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">mOS [95% CI], months</td>
                        <td align="center" rowspan="1" colspan="1">7.8 [6.1–20.1]</td>
                        <td align="center" rowspan="1" colspan="1">15.6 [7.0, NE]</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cncr34366-ntgp-0002">
                    <fn id="cncr34366-note-0005">
                      <p><italic toggle="yes">Note:</italic> Data cutoff: July 23, 2021.</p>
                    </fn>
                    <fn id="cncr34366-note-0006">
                      <p>Abbreviations: CBR, clinical benefit rate defined as percentage of patients with confirmed tumor responses (as assessed by the investigators) of CR, PR, and durable SD (SD of ≥4 months' duration); CR, complete response; mPFS, median progression‐free survival; mOS, median overall survival; NE, not estimable; NEN, neuroendocrine neoplasm; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="cncr34366-sec-0016">
                <title>Pharmacokinetics and pharmacodynamics</title>
                <p>All patients with NENs in the dose‐expansion arm (<italic toggle="yes">n</italic> = 16) were evaluable for pharmacokinetic assessments. Pharmacokinetic parameters are shown in Figure <xref rid="cncr34366-fig-0002" ref-type="fig">2</xref>. Consistent with the dose‐escalation arm of the study, the peak CC‐90011 concentration was observed at an approximate median of 4 hours after treatment (Figure <xref rid="cncr34366-fig-0002" ref-type="fig">2A</xref>). Negligible accumulation occurred with repeat dosing based on the AUC, and systemic exposures were similar between both arms of the study (Figure <xref rid="cncr34366-fig-0002" ref-type="fig">2B</xref>).<xref rid="cncr34366-bib-0022" ref-type="bibr"><sup>22</sup></xref>
</p>
                <fig position="float" fig-type="Figure" id="cncr34366-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <p>Mean CC‐90011 concentration‐time profiles and pharmacokinetic parameters on days 1 and 22 of cycle 1. <sup>a</sup>Data are the median (range) for t<sub>max</sub> and the geometric mean (% coefficient of variation) for all other parameters. AUC<sub>0–24</sub> indicates the area under the curve during 24 hours; AUC<sub>0 − t</sub>, area under the plasma drug concentration–time curve up to time <italic toggle="yes">t</italic>; C<sub>max</sub>, maximum observed plasma concentration; QW, once per week; t<sub>max</sub>, time of first occurrence of C<sub>max</sub> (data cutoff: June 27, 2019).</p>
                  </caption>
                  <graphic xlink:href="CNCR-128-3185-g003" position="anchor" id="jats-graphic-3"/>
                </fig>
                <p>Similar to results observed in the dose‐escalation arm at the 60‐mg dose, a downregulation ≥50% in <italic toggle="yes">MMD</italic> gene expression in the peripheral blood was observed in the dose‐expansion arm (Figure <xref rid="cncr34366-fig-0003" ref-type="fig">3A</xref>). Circulating tumor neuropeptide CgA levels decreased 0%–82% in the dose‐expansion arm (Figure <xref rid="cncr34366-fig-0003" ref-type="fig">3B</xref>). A CgA nadir at &lt;50% of the baseline level was associated with longer time on treatment, with SD lasting &gt;6 months, and pro‐GRP levels decreased in 15 of 16 patients who had NENs in the dose‐expansion arm (Figure <xref rid="cncr34366-fig-0003" ref-type="fig">3C</xref>). Moreover, a decrease &gt;30% was observed in 11 of 16 patients (65%). A higher pro‐GRP nadir at &gt;70% of the baseline level was associated with a shorter time on treatment (&lt;6 months). Further analysis of pharmacodynamic markers for CC‐90011 are ongoing.</p>
                <fig position="float" fig-type="Figure" id="cncr34366-fig-0003">
                  <label>Figure 3</label>
                  <caption>
                    <p>Changes in (A) peripheral blood pharmacodynamic marker <italic toggle="yes">MMD</italic> mRNA expression, (B) circulating tumor neuropeptide CgA, and (C) circulating tumor neuropeptide pro‐GRP (C). (A) Mean levels of <italic toggle="yes">MMD</italic> mRNA relative to pretreatment baseline over time after the initial dose are shown in 16 patients with NENs. Error bars indicate standard deviations. (B,C) Baseline, nadir, and last measurements are shown, with each cluster of columns representing one patient. C also depicts pro‐GRP nadir levels relative to baseline versus the time on study, with each dot representing one patient (data cutoff: June 27, 2019, for A and B; June 1, 2021, for C). CgA indicates chromogranin A; <italic toggle="yes">MMD</italic>, monocyte‐to‐macrophage differentiation–associated; mRNA, messenger RNA; NENs, neuroendocrine neoplasms; pro‐GRP, prograstrin‐releasing peptide; QW, once per week.</p>
                  </caption>
                  <graphic xlink:href="CNCR-128-3185-g002" position="anchor" id="jats-graphic-5"/>
                </fig>
              </sec>
              <sec id="cncr34366-sec-0017">
                <title>Safety</title>
                <p>Treatment‐emergent AEs (TEAEs), which are listed in Table <xref rid="cncr34366-tbl-0003" ref-type="table">3</xref>, primarily consisted of hematologic events, including thrombocytopenia, which is an on‐target effect. Among patients with NENs, the most common any‐grade and grade 3 and 4 TEAE was thrombocytopenia (<italic toggle="yes">n</italic> = 11 [69%] and <italic toggle="yes">n</italic> = 6 [38%], respectively). For patients with R/R MZL, thrombocytopenia and fatigue/asthenia were the most common TEAEs (<italic toggle="yes">n</italic> = 2; 67%, each) and were grade 1 or 2. Other common grade 3 and 4 TEAEs were neutropenia (<italic toggle="yes">n</italic> = 3; two patients with NENs and one with R/R MZL) and fatigue/asthenia (<italic toggle="yes">n</italic> = 3 patients with NENs). These AEs were reversible, easily manageable, and mitigated by dose modifications. The most common any‐grade treatment‐related AE (TRAE) in the NEN cohort was thrombocytopenia (<italic toggle="yes">n</italic> = 11; 69%), followed by fatigue/asthenia (<italic toggle="yes">n</italic> = 6; 38%), and anemia (<italic toggle="yes">n</italic> = 4; 25%); in the R/R MZL cohort, thrombocytopenia was the most common any‐grade TRAE (<italic toggle="yes">n</italic> = 2; 67%). The most common grade 3 and 4 TRAEs included thrombocytopenia (<italic toggle="yes">n</italic> = 6; all in the NEN cohort) and neutropenia (<italic toggle="yes">n</italic> = 3; two patients with NENs and one with R/R MZL; see Table S2).</p>
                <table-wrap position="float" id="cncr34366-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Treatment‐Emergent Adverse Events<xref rid="cncr34366-note-0009" ref-type="table-fn"><sup>a</sup></xref>
</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="center" span="1"/>
                    <col align="center" span="1"/>
                    <col align="center" span="1"/>
                    <col align="center" span="1"/>
                    <col align="center" span="1"/>
                    <col align="center" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1"/>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Dose escalation</th>
                        <th align="center" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Dose expansion</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Characteristic</th>
                        <th align="center" rowspan="1" colspan="1">Any grade, <italic toggle="yes">n</italic> = 50</th>
                        <th align="center" rowspan="1" colspan="1">Grade 3/4, <italic toggle="yes">n</italic> = 50</th>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Any grade, <italic toggle="yes">n</italic> = 19</th>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Grade 3/4, <italic toggle="yes">n</italic> = 19</th>
                      </tr>
                      <tr>
                        <th style="padding-left:10%" align="left" rowspan="1" colspan="1">≥1 event</th>
                        <th align="center" rowspan="1" colspan="1">48 (96)</th>
                        <th align="center" rowspan="1" colspan="1">24 (48)</th>
                        <th colspan="2" align="center" rowspan="1">19 (100)</th>
                        <th colspan="2" align="center" rowspan="1">13 (68)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Cohort</th>
                        <th align="center" rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">NEN, n = 16</th>
                        <th align="center" rowspan="1" colspan="1">R/R MZL. <italic toggle="yes">n</italic> = 3</th>
                        <th align="center" rowspan="1" colspan="1">NEN, <italic toggle="yes">n</italic> = 16</th>
                        <th align="center" rowspan="1" colspan="1">R/R MZL, <italic toggle="yes">n</italic> = 3</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Fatigue/asthenia</td>
                        <td align="center" rowspan="1" colspan="1">24 (48)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">9 (56)</td>
                        <td align="center" rowspan="1" colspan="1">2 (67)</td>
                        <td align="center" rowspan="1" colspan="1">3 (19)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Thrombocytopenia</td>
                        <td align="center" rowspan="1" colspan="1">23 (46)</td>
                        <td align="center" rowspan="1" colspan="1">12 (24)</td>
                        <td align="center" rowspan="1" colspan="1">11 (69)</td>
                        <td align="center" rowspan="1" colspan="1">2 (67)</td>
                        <td align="center" rowspan="1" colspan="1">6 (38)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Vomiting</td>
                        <td align="center" rowspan="1" colspan="1">14 (28)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Anemia</td>
                        <td align="center" rowspan="1" colspan="1">14 (28)</td>
                        <td align="center" rowspan="1" colspan="1">3 (6)</td>
                        <td align="center" rowspan="1" colspan="1">6 (38)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                        <td align="center" rowspan="1" colspan="1">1 (6)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Nausea</td>
                        <td align="center" rowspan="1" colspan="1">11 (22)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">5 (31)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Constipation</td>
                        <td align="center" rowspan="1" colspan="1">11 (22)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">5 (31)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Pyrexia</td>
                        <td align="center" rowspan="1" colspan="1">10 (20)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Decreased appetite</td>
                        <td align="center" rowspan="1" colspan="1">10 (20)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">3 (19)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Diarrhea</td>
                        <td align="center" rowspan="1" colspan="1">10 (20)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">5 (31)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Arthralgia</td>
                        <td align="center" rowspan="1" colspan="1">9 (18)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">6 (38)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Abdominal pain</td>
                        <td align="center" rowspan="1" colspan="1">7 (14)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Back pain</td>
                        <td align="center" rowspan="1" colspan="1">7 (14)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (6)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Increased ALT</td>
                        <td align="center" rowspan="1" colspan="1">6 (12)</td>
                        <td align="center" rowspan="1" colspan="1">2 (4)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Increased AST</td>
                        <td align="center" rowspan="1" colspan="1">6 (12)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">1 (6)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Neutropenia</td>
                        <td align="center" rowspan="1" colspan="1">6 (12)</td>
                        <td align="center" rowspan="1" colspan="1">4 (8)</td>
                        <td align="center" rowspan="1" colspan="1">3 (19)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cough</td>
                        <td align="center" rowspan="1" colspan="1">6 (12)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">3 (19)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Dyspnea</td>
                        <td align="center" rowspan="1" colspan="1">5 (10)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hypokalemia</td>
                        <td align="center" rowspan="1" colspan="1">5 (10)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Headache</td>
                        <td align="center" rowspan="1" colspan="1">5 (10)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Tumor pain</td>
                        <td align="center" rowspan="1" colspan="1">5 (10)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Dysgeusia</td>
                        <td align="center" rowspan="1" colspan="1">3 (6)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">4 (25)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Pruritus</td>
                        <td align="center" rowspan="1" colspan="1">3 (6)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Dizziness</td>
                        <td align="center" rowspan="1" colspan="1">3 (6)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Bronchitis</td>
                        <td align="center" rowspan="1" colspan="1">2 (4)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Epistaxis</td>
                        <td align="center" rowspan="1" colspan="1">2 (4)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">3 (19)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Lipase increased</td>
                        <td align="center" rowspan="1" colspan="1">2 (4)</td>
                        <td align="center" rowspan="1" colspan="1">2 (4)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Peripheral sensory neuropathy</td>
                        <td align="center" rowspan="1" colspan="1">2 (4)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Acute kidney injury</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (6)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Bone pain</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">1 (33)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hepatic pain</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (6)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Musculoskeletal pain</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (6)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Sciatica</td>
                        <td align="center" rowspan="1" colspan="1">1 (2)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (13)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cncr34366-ntgp-0003">
                    <fn id="cncr34366-note-0007">
                      <p><italic toggle="yes">Note:</italic> Data cutoff: July 23, 2021.</p>
                    </fn>
                    <fn id="cncr34366-note-0008">
                      <p>Abbreviations: NEN, neuroendocrine neoplasm; R/R MZL, relapsed/refractory marginal zone lymphoma.</p>
                    </fn>
                    <fn id="cncr34366-note-0009">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Treatment‐emergent adverse events occurring in ≥10% of patients in either arm of the study are reported. Events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>In the dose‐expansion cohort, six patients, all in the NEN cohort, experienced at least one serious TEAE (see Table S3). These serious AEs included thrombocytopenia, anemia, chest pain, fatigue, general physical health deterioration, hepatic hemorrhage, hepatic pain, biliary tract infection, upper respiratory tract infection, oxygen saturation decrease, pulmonary hemorrhage, and respiratory failure (<italic toggle="yes">n</italic> = 1 each). One patient in the dose‐expansion arm had a TEAE (upper respiratory tract infection) with an outcome of death, which was caused by the progression of underlying disease and was not considered treatment‐related.</p>
                <p>Of the 19 patients in the dose‐expansion arm, including both the NEN cohort and the MZL cohort, five (26%) had at least one TEAE leading to a dose reduction of CC‐90011, all of which were for hematologic events. Five patients (26%) had thrombocytopenia, one (5%) had anemia, and one (5%) had neutropenia. Eleven patients (58%) had at least one TEAE leading to a dose interruption of CC‐90011, and the majority (<italic toggle="yes">n</italic> = 9; 47%) had manageable hematologic events. No patients in the dose‐expansion arm had a TEAE leading to treatment discontinuation.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cncr34366-sec-0018">
              <title>DISCUSSION</title>
              <p>Several LSD1 inhibitors are in clinical development for the treatment of cancer, most of which are irreversible and have safety signals in clinical trials.<xref rid="cncr34366-bib-0029" ref-type="bibr"><sup>29</sup></xref> In a first‐in‐human study, the irreversible LSD1 inhibitor iadademstat (ORY‐1001) caused toxicities, including thrombocytopenia, anemia, and febrile neutropenia, as well as deaths possibly related to iadademstat.<xref rid="cncr34366-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="cncr34366-bib-0031" ref-type="bibr"><sup>31</sup></xref> In a phase 1 dose‐escalation study of GSK2879552 in R/R SCLC,<xref rid="cncr34366-bib-0032" ref-type="bibr"><sup>32</sup></xref> favorable pharmacokinetic properties were demonstrated, but the rate of AEs, especially serious AEs, was high. Because that irreversible LSD1 inhibitor did not have a favorable risk–benefit profile, the study was subsequently terminated. CC‐90011 is an oral, potent, selective, reversible inhibitor of LSD1 that was well tolerated in the dose‐escalation arm of the CC‐90011‐ST‐001 study.<xref rid="cncr34366-bib-0022" ref-type="bibr"><sup>22</sup></xref> Thrombocytopenia was the only dose‐limiting toxicity reported, and all dose‐limiting toxicities were reversible and easily manageable.<xref rid="cncr34366-bib-0022" ref-type="bibr"><sup>22</sup></xref> Safety results from the dose‐expansion arm of the current study confirmed findings from the dose‐escalation arm in that heavily pretreated patient population.<xref rid="cncr34366-bib-0022" ref-type="bibr"><sup>22</sup></xref> Most AEs with monotherapy were mild or moderate, reversible, and easily managed with dose modifications, supporting the exploration of CC‐90011 in combinations. Importantly, none of the TEAEs in the dose‐expansion arm led to discontinuation of treatment because of toxicity, and no febrile neutropenia was observed. The most frequent toxicity was thrombocytopenia, which is an on‐target effect of CC‐90011, consistent with the role of LSD1 as a key regulator of platelet maturation.<xref rid="cncr34366-bib-0033" ref-type="bibr"><sup>33</sup></xref> The on‐target thrombocytopenia reported was reversible and easily manageable with dose modifications.</p>
              <p>Unlike chemotherapy that induces apoptosis, CC‐90011 affects platelet maturation; therefore, the observed toxicity in response to CC‐90011 treatment is readily reversible. Moreover, because overall toxicity is largely limited to manageable thrombocytopenia, CC‐90011 is a promising agent for combination therapy. CC‐90011 has been safely combined with cisplatin/etoposide and with carboplatin/etoposide in first‐line extensive‐stage SCLC,<xref rid="cncr34366-bib-0021" ref-type="bibr"><sup>21</sup></xref> with nivolumab in the second line for SCLC or squamous nonsmall cell lung cancer,<xref rid="cncr34366-bib-0034" ref-type="bibr"><sup>34</sup></xref> with abiraterone/prednisone in castration‐resistant prostate cancer,<xref rid="cncr34366-bib-0035" ref-type="bibr"><sup>35</sup></xref> and with azacitidine in acute myeloid leukemia.<xref rid="cncr34366-bib-0036" ref-type="bibr"><sup>36</sup></xref>
</p>
              <p>CC‐90011 pharmacokinetic parameters in the dose‐expansion arm were consistent with results observed in the dose‐escalation arm. The long terminal half‐life of CC‐90011 supports dosing once per week. These results also suggest the similarity of CC‐90011 exposure parameters across different tumor types. Pharmacodynamic biomarker data demonstrated that CC‐90011 decreased levels of the neuroendocrine peptides CgA and pro‐GRP and decreased gene expression of a blood pharmacodynamic marker, <italic toggle="yes">MMD</italic>, by ≥50%. Our previous findings demonstrated that downregulation of <italic toggle="yes">MMD</italic> RNA is a marker of target engagement by CC‐90011.<xref rid="cncr34366-bib-0037" ref-type="bibr"><sup>37</sup></xref> Furthermore, CgA and pro‐GRP are secreted by the tumors and are widely accepted biomarkers for assessing NENs,<xref rid="cncr34366-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="cncr34366-bib-0028" ref-type="bibr"><sup>28</sup></xref> and a CgA decrease may be predictive of response to therapy in these patients.<xref rid="cncr34366-bib-0038" ref-type="bibr"><sup>38</sup></xref> Of note, CgA nadir levels ≤50% of baseline were associated with a longer time on treatment, as previously shown.<xref rid="cncr34366-bib-0039" ref-type="bibr"><sup>39</sup></xref> Conversely, higher pro‐GRP nadir levels ≥70% of baseline were associated with shorter on‐treatment duration. These data suggest target engagement activity with CC‐90011 and biologic responses of tumor cells to CC‐90011.</p>
              <p>In terms of efficacy, the longer follow‐up of the dose‐escalation arm revealed prolonged, durable responses in a patient with R/R MZL who achieved a CR after three or four previously failed treatments (currently ongoing in cycle 58 as of April 2022) and in a patient with solitary fibrous tumor who achieved a PR in cycle 36. The patient with the solitary fibrous tumor had previously received repeated treatment for recurring low‐grade sarcoma. The deepening of the response to a PR after approximately 3 years on treatment with SD indicates that prolonged CC‐90011 treatment could lead to a better response with minimal toxicity.</p>
              <p>Efficacy results were consistent with the mechanism of action of CC‐90011. LSD1 inhibitors have been shown to drive tumor differentiation rather than trigger tumor apoptosis, so single‐agent activity in highly aggressive tumors was not expected. Rather, LSD1 inhibitors like CC‐90011 are expected to have more pronounced effects on malignancies with a more indolent course, such as low‐grade NENs, or a limited tumor burden, such as the patient with R/R MZL who was receiving ongoing treatment in cycle 58. The management of NENs, a heterogenous group of tumors that commonly originate in the lung, gastrointestinal tract, and pancreas, represents a clinical challenge because of the lack of a standard treatment strategy for this disease.<xref rid="cncr34366-bib-0040" ref-type="bibr"><sup>40</sup></xref>, <xref rid="cncr34366-bib-0041" ref-type="bibr"><sup>41</sup></xref>, <xref rid="cncr34366-bib-0042" ref-type="bibr"><sup>42</sup></xref> The number of new cases of NENs is rising, potentially because of increased detection.<xref rid="cncr34366-bib-0042" ref-type="bibr"><sup>42</sup></xref>, <xref rid="cncr34366-bib-0043" ref-type="bibr"><sup>43</sup></xref>, <xref rid="cncr34366-bib-0044" ref-type="bibr"><sup>44</sup></xref> Given the heterogeneity of NENs, their management and treatment is complex.<xref rid="cncr34366-bib-0045" ref-type="bibr"><sup>45</sup></xref> Recently developed treatments include somatostatin analogs, everolimus,<xref rid="cncr34366-bib-0046" ref-type="bibr"><sup>46</sup></xref> temozolomide plus capecitabine, sunitinib, and peptide receptor radionuclide therapy.<xref rid="cncr34366-bib-0047" ref-type="bibr"><sup>47</sup></xref> Despite an increase in treatment options for patients with NENs, an unmet medical need remains for additional novel therapies that provide optimal disease management.</p>
              <p>Taken together, the efficacy results from the dose‐escalation and dose‐expansion arms of the current study suggest that CC‐90011 has broad clinical activity across tumor types, including bronchial NENs and R/R MZL. In the dose‐expansion arm, prolonged SD for &gt;4 months was observed in 37% of patients, and three patients had SD lasting ≥9 months. Notably, one patient with bronchial NENs was still ongoing treatment in cycle 46 at the time of the writing of this article. In patients with bronchial NENs, the median PFS of 4.6 months was longer than the typical PFS observed in the prior therapies each of these patients received.</p>
              <p>In conclusion, CC‐90011 may have a significant advantage over other LSD1 inhibitors based on the reversible mechanism of action and the established, optimal dose/schedule that induced mostly mild and easily managed toxicity. No new safety concerns or late toxicities were identified with a longer follow‐up of approximately 5 years and &gt;4 years of treatment. The observed clinical activity was particularly evident in some patients who had more indolent diseases, such as low‐grade bronchial NENs. or in malignancies with a limited tumor burden, such as MZL. The clinical activity of CC‐90011, along with the prolonged, durable responses and convenient once‐per‐week dosing, provide support for further investigations of CC‐90011 either as maintenance monotherapy or in combination with other cancer treatments.</p>
            </sec>
            <sec id="cncr34366-sec-0020">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Antoine Hollebecque</bold>, <bold>Zariana Nikolova</bold>, and <bold>Johann S. de Bono:</bold> Conceptualization, supervision, and writing–original draft. <bold>Marina Arias</bold>, <bold>Juan de Alvaro</bold>, <bold>Josep L. Parra‐Palau</bold>, <bold>Tania Sánchez‐Pérez</bold>, <bold>Ida Aronchik</bold>, <bold>Ellen H. Filvaroff</bold>, <bold>Manisha Lamba</bold>, and <bold>Zariana Nikolova:</bold> Data curation, formal analysis, verification, methodology, and writing–original draft. All authors contributed to investigation, visualization, resources, and writing–review and editing.</p>
            </sec>
            <sec id="cncr34366-sec-0021">
              <title>FUNDING INFORMATION</title>
              <p>This study was supported by Bristol Myers Squibb, Princeton, New Jersey, USA. Writing and editorial assistance was provided by Bio Connections, LLC, funded by Bristol Myers Squibb.</p>
            </sec>
            <sec sec-type="COI-statement" id="cncr34366-sec-0022">
              <title>CONFLICT OF INTEREST</title>
              <p>Antoine Hollebecque reports personal fees from Amgen, Bristol Myers Squibb (BMS), Debiopharm, Eisai, Incyte, and QED Therapeutics; nonfinancial support from Eli Lilly &amp; Company (Lilly) and Incyte; and other support from AstraZeneca, Roche, and Servier outside the supported work. Ruth Plummer reports honoraria from Ellipses; personal fees from Bayer, Biosceptre, BMS, Clovis Oncology, Cybrexa, Genmab, Karus Therapeutics, Novartis, OCTIMET, Pierre Fabre, and Sanofi Aventis (Sanofi); research funding from AstraZeneca; speakers' fees from AstraZeneca, Bayer, BMS, Novartis, and Tesaro; intellectual property with Clovis Oncology; and travel fees from BMS and Merck Sharp &amp; Dohme (MSD) outside the submitted work. Jaume Capdevila reports personal fees and speakers' fees from Advanced Accelerator Applications (AAA; a Novartis company), Amgen, AstraZeneca, Bayer, Eisai, Ipsen, Merck, Novartis, Pfizer, and Sanofi; research funding from AAA, AstraZeneca, Bayer, Celgene Corporation/BMS, Eisai, Ipsen, Novartis, and Pfizer; and travel fees from Eisai, Ipsen, and Pfizer outside the submitted work. Giuseppe Curigliano reports personal fees from AstraZeneca, Ellipses, Daiichi Sankyo (Daiichi), Lilly, Merck, Novartis, Pfizer, Roche, and Seagen; research funding from Merck; and speakers' fees from Daiichi, Lilly, Novartis, Pfizer, and Seagen outside the submitted work. Victor Moreno reports personal fees from BMS; speakers' fees from BMS, BMS/Loxo, and Regeneron; and travel fees from BMS and Regeneron outside the submitted work. Filippo de Braud reports personal fees from BMS, EMD Serono, Incyte, Menarini, Roche, MSD, Nerviano Medical Sciences, Novartis, and Sanofi; research funding from Basilea Pharmaceutica, BMS, Daiichi, Exelixis Inc., Roche, Ignyta Operating, Janssen‐Cilag, Kymab, Loxo Oncology, MedImmune, Merck, Novartis, Pfizer, and Tesaro; and speakers' fees from Accmed, Amgen, BMS, Healthcare Research &amp; Pharmacoepidemiology, Incyte, Merck, Nadirex, Pfizer, Roche, Servier, and Sanofi outside the submitted work. Patricia Martin‐Romano reports employment with Novartis; personal fees from ABT Pharma; research funding from AbbVie, Adaptimmune, Adlai Nortye, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argenx, Astex Pharmaceuticals, AstraZeneca, Aveo, Basilea Pharmaceutica, Bayer Healthcare, BBB Technologies, BeiGene, BicycleTx, Blueprint Medicines, BMS/Celgene Corporation, Boehringer Ingelheim, Boston Pharmaceuticals, Chugai Pharmaceutical, Clovis, Cullinan‐Apollo, CureVac, Daiichi, Debiopharm, Eisai, Lilly, Exelixis, Faron Pharmaceuticals, Forma Therapeutics, GamaMabs, Genentech, GlaxoSmithKline, H3 Biomedicine, Roche, ImCheck Therapeutics, INCA, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, iTeos Belgium, Janssen‐Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm, Lilly France, Loxo Oncology, Lytix Biopharma, Medicament, Medimmune, Menarini, MSD‐Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners, Nanobiotix, Nektar Therapeutics, Novartis Pharma, OCTIMET Oncology, OncoEthix, Oncopeptides, Orion Pharma, OSE Pharma, Pfizer, PharmaMar, Pierre Fabre, Roche, Sanofi, Seattle Genetics, Sotio, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, and Xencor; and nonfinancial support from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, GlaxoSmithKline, Medimmune, Merck, NH TherAguiX, Pfizer, and Roche outside the submitted work. Eric Baudin reports research funding from AAA and Pfizer and speakers' fees from AAA, Hutchinson Pharma, Ipsen, Novartis, and Pfizer outside the submitted work. Juan de Alvaro is a former employee of Celgene Corporation/BMS. Josep L. Parra‐Palau and Zariana Nikolova report employment, stock ownership, and travel fees from Celgene Corporation/BMS. Tania Sánchez‐Pérez and Ida Aronchik report employment by Celgene Corporation/BMS. Ellen H. Filvaroff reports employment by Celgene Corporation/BMS; stock ownership in Amgen, BMS, Genentech/Roche, and Gilead; intellectual property with BMS; and travel fees from BMS outside the submitted work. Manisha Lamba reports employment and stock ownership with BMS and intellectual property with Pfizer. Johann S. de Bono reports personal and/or travel fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi, Genentech/Roche, Genmab, GlaxoSmithKline, Janssen, Merck Serono, MSD, Menarini Silicon Biosystems, Orion, Pfizer, Sanofi, Sierra Oncology, and Taiho; and research funding from Astellas, AstraZeneca, Bayer, Celgene Corporation/BMS, CellCentric, Daiichi, Genentech, GlaxoSmithKline, Janssen, Merck Serono, MSD, Menarini, Orion, Sanofi, Sierra Oncology, and Taiho. The remaining authors made no disclosures.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="cncr34366-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>Appendix S1</bold> Supporting Information</p>
                </caption>
                <media xlink:href="CNCR-128-3185-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="cncr34366-sec-0019">
              <title>ACKNOWLEDGMENTS</title>
              <p>We thank the patients and their families as well as the coinvestigators and site staff who participated in the trial. This study was supported by Bristol Myers Squibb, Princeton, New Jersey, USA. Writing and editorial assistance was provided by Bio Connections, LLC, funded by Bristol Myers Squibb.</p>
            </ack>
            <sec sec-type="data-availability" id="cncr34366-sec-0024">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>Bristol Myers Squibb company policy on data sharing may be found online (<ext-link xlink:href="https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.bms.com/researchers‐and‐partners/independent‐research/data‐sharing‐request‐process.html</ext-link>).</p>
            </sec>
            <ref-list content-type="cited-references" id="cncr34366-bibl-0001">
              <title>REFERENCES</title>
              <ref id="cncr34366-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0001"><string-name><surname>Shi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lan</surname><given-names>F</given-names></string-name>, <string-name><surname>Matson</surname><given-names>C</given-names></string-name>, et al. <article-title>Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</article-title>. <source>Cell.</source><year>2004</year>;<volume>119</volume>(<issue>7</issue>):<fpage>941</fpage>‐<lpage>953</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2004.12.012</pub-id>
<pub-id pub-id-type="pmid">15620353</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0002"><string-name><surname>Metzger</surname><given-names>E</given-names></string-name>, <string-name><surname>Wissmann</surname><given-names>M</given-names></string-name>, <string-name><surname>Yin</surname><given-names>N</given-names></string-name>, et al. <article-title>LSD1 demethylates repressive histone marks to promote androgen‐receptor‐dependent transcription</article-title>. <source>Nature.</source><year>2005</year>;<volume>437</volume>(<issue>7057</issue>):<fpage>436</fpage>‐<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature04020</pub-id>
<pub-id pub-id-type="pmid">16079795</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0003"><string-name><surname>Scoumanne</surname><given-names>A</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X</given-names></string-name>. <article-title>The lysine‐specific demethylase 1 is required for cell proliferation in both p53‐dependent and ‐independent manners</article-title>. <source>J Biol Chem.</source><year>2007</year>;<volume>282</volume>(<issue>21</issue>):<fpage>15471</fpage>‐<lpage>15475</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M701023200</pub-id>
<pub-id pub-id-type="pmid">17409384</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0004"><string-name><surname>Dimitrova</surname><given-names>E</given-names></string-name>, <string-name><surname>Turberfield</surname><given-names>AH</given-names></string-name>, <string-name><surname>Klose</surname><given-names>RJ</given-names></string-name>. <article-title>Histone demethylases in chromatin biology and beyond</article-title>. <source>EMBO Rep.</source><year>2015</year>;<volume>16</volume>(<issue>12</issue>):<fpage>1620</fpage>‐<lpage>1639</lpage>. doi:<pub-id pub-id-type="doi">10.15252/embr.201541113</pub-id>
<pub-id pub-id-type="pmid">26564907</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0005"><string-name><surname>Adamo</surname><given-names>A</given-names></string-name>, <string-name><surname>Sese</surname><given-names>B</given-names></string-name>, <string-name><surname>Boue</surname><given-names>S</given-names></string-name>, et al. <article-title>LSD1 regulates the balance between self‐renewal and differentiation in human embryonic stem cells</article-title>. <source>Nat Cell Biol.</source><year>2011</year>;<volume>13</volume>(<issue>6</issue>):<fpage>652</fpage>‐<lpage>659</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ncb2246</pub-id>
<pub-id pub-id-type="pmid">21602794</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0006"><string-name><surname>Foster</surname><given-names>CT</given-names></string-name>, <string-name><surname>Dovey</surname><given-names>OM</given-names></string-name>, <string-name><surname>Lezina</surname><given-names>L</given-names></string-name>, et al. <article-title>Lysine‐specific demethylase 1 regulates the embryonic transcriptome and CoREST stability</article-title>. <source>Mol Cell Biol.</source><year>2010</year>;<volume>30</volume>(<issue>20</issue>):<fpage>4851</fpage>‐<lpage>4863</lpage>. doi:<pub-id pub-id-type="doi">10.1128/MCB.00521-10</pub-id>
<pub-id pub-id-type="pmid">20713442</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0007"><string-name><surname>Pollock</surname><given-names>JA</given-names></string-name>, <string-name><surname>Larrea</surname><given-names>MD</given-names></string-name>, <string-name><surname>Jasper</surname><given-names>JS</given-names></string-name>, <string-name><surname>McDonnell</surname><given-names>DP</given-names></string-name>, <string-name><surname>McCafferty</surname><given-names>DG</given-names></string-name>. <article-title>Lysine‐specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα‐dependent and ‐independent manners</article-title>. <source>ACS Chem Biol.</source><year>2012</year>;<volume>7</volume>(<issue>7</issue>):<fpage>1221</fpage>‐<lpage>1231</lpage>. doi:<pub-id pub-id-type="doi">10.1021/cb300108c</pub-id>
<pub-id pub-id-type="pmid">22533360</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0008"><string-name><surname>Cho</surname><given-names>HS</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>T</given-names></string-name>, <string-name><surname>Dohmae</surname><given-names>N</given-names></string-name>, et al. <article-title>Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells</article-title>. <source>Cancer Res.</source><year>2011</year>;<volume>71</volume>(<issue>3</issue>):<fpage>655</fpage>‐<lpage>660</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.Can-10-2446</pub-id>
<pub-id pub-id-type="pmid">21115810</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0009"><string-name><surname>Lv</surname><given-names>T</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>D</given-names></string-name>, <string-name><surname>Miao</surname><given-names>X</given-names></string-name>, et al. <article-title>Over‐expression of LSD1 promotes proliferation, migration and invasion in non‐small cell lung cancer</article-title>. <source>PLoS One.</source><year>2012</year>;<volume>7</volume>(<issue>4</issue>):<elocation-id>e35065</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0035065</pub-id><pub-id pub-id-type="pmid">22493729</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0010"><string-name><surname>Hayami</surname><given-names>S</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>JD</given-names></string-name>, <string-name><surname>Cho</surname><given-names>HS</given-names></string-name>, et al. <article-title>Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers</article-title>. <source>Int J Cancer.</source><year>2011</year>;<volume>128</volume>(<issue>3</issue>):<fpage>574</fpage>‐<lpage>586</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.25349</pub-id>
<pub-id pub-id-type="pmid">20333681</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0011"><string-name><surname>Jin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ma</surname><given-names>D</given-names></string-name>, <string-name><surname>Gramyk</surname><given-names>T</given-names></string-name>, et al. <article-title>Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest</article-title>. <source>Biochem Biophys Res Commun.</source><year>2019</year>;<volume>515</volume>(<issue>1</issue>):<fpage>214</fpage>‐<lpage>221</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2019.05.118</pub-id>
<pub-id pub-id-type="pmid">31146914</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0012"><string-name><surname>Ding</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>ZM</given-names></string-name>, <string-name><surname>Xia</surname><given-names>Y</given-names></string-name>, et al. <article-title>LSD1‐mediated epigenetic modification contributes to proliferation and metastasis of colon cancer</article-title>. <source>Br J Cancer.</source><year>2013</year>;<volume>109</volume>(<issue>4</issue>):<fpage>994</fpage>‐<lpage>1003</lpage>. doi:<pub-id pub-id-type="doi">10.1038/bjc.2013.364</pub-id>
<pub-id pub-id-type="pmid">23900215</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0013"><string-name><surname>Harris</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name><surname>Lynch</surname><given-names>JT</given-names></string-name>, et al. <article-title>The histone demethylase KDM1A sustains the oncogenic potential of MLL‐AF9 leukemia stem cells</article-title>. <source>Cancer Cell.</source><year>2012</year>;<volume>21</volume>(<issue>4</issue>):<fpage>473</fpage>‐<lpage>487</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccr.2012.03.014</pub-id>
<pub-id pub-id-type="pmid">22464800</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0014"><string-name><surname>Murray‐Stewart</surname><given-names>T</given-names></string-name>, <string-name><surname>Woster</surname><given-names>PM</given-names></string-name>, <string-name><surname>Casero</surname><given-names>RA</given-names><suffix>Jr</suffix></string-name>. <article-title>The re‐expression of the epigenetically silenced e‐cadherin gene by a polyamine analogue lysine‐specific demethylase‐1 (LSD1) inhibitor in human acute myeloid leukemia cell lines</article-title>. <source>Amino Acids.</source><year>2014</year>;<volume>46</volume>(<issue>3</issue>):<fpage>585</fpage>‐<lpage>594</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00726-013-1485-1</pub-id>
<pub-id pub-id-type="pmid">23508577</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0015"><string-name><surname>Schenk</surname><given-names>T</given-names></string-name>, <string-name><surname>Chen</surname><given-names>WC</given-names></string-name>, <string-name><surname>Gollner</surname><given-names>S</given-names></string-name>, et al. <article-title>Inhibition of the LSD1 (KDM1A) demethylase reactivates the all‐trans‐retinoic acid differentiation pathway in acute myeloid leukemia</article-title>. <source>Nat Med.</source><year>2012</year>;<volume>18</volume>(<issue>4</issue>):<fpage>605</fpage>‐<lpage>611</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.2661</pub-id>
<pub-id pub-id-type="pmid">22406747</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0016"><string-name><surname>Davies</surname><given-names>A</given-names></string-name>, <string-name><surname>Zoubeidi</surname><given-names>A</given-names></string-name>, <string-name><surname>Selth</surname><given-names>LA</given-names></string-name>. <article-title>The epigenetic and transcriptional landscape of neuroendocrine prostate cancer</article-title>. <source>Endocr Relat Cancer.</source><year>2020</year>;<volume>27</volume>(<issue>2</issue>):<fpage>R35</fpage>‐<lpage>R50</lpage>. doi:<pub-id pub-id-type="doi">10.1530/ERC-19-0420</pub-id>
<pub-id pub-id-type="pmid">31804971</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0017"><string-name><surname>Jotatsu</surname><given-names>T</given-names></string-name>, <string-name><surname>Yagishita</surname><given-names>S</given-names></string-name>, <string-name><surname>Tajima</surname><given-names>K</given-names></string-name>, et al. <article-title>LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer</article-title>. <source>Biochem Biophys Rep.</source><year>2017</year>;<volume>9</volume>:<fpage>86</fpage>‐<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrep.2016.11.015</pub-id>
<pub-id pub-id-type="pmid">28955993</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0018"><string-name><surname>Niebel</surname><given-names>D</given-names></string-name>, <string-name><surname>Kirfel</surname><given-names>J</given-names></string-name>, <string-name><surname>Janzen</surname><given-names>V</given-names></string-name>, <string-name><surname>Holler</surname><given-names>T</given-names></string-name>, <string-name><surname>Majores</surname><given-names>M</given-names></string-name>, <string-name><surname>Gutgemann</surname><given-names>I</given-names></string-name>. <article-title>Lysine‐specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms</article-title>. <source>Blood.</source><year>2014</year>;<volume>124</volume>(<issue>1</issue>):<fpage>151</fpage>‐<lpage>152</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2014-04-569525</pub-id>
<pub-id pub-id-type="pmid">24993879</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0019"><string-name><surname>Hatzi</surname><given-names>K</given-names></string-name>, <string-name><surname>Geng</surname><given-names>H</given-names></string-name>, <string-name><surname>Doane</surname><given-names>AS</given-names></string-name>, et al. <article-title>Histone demethylase LSD1 is required for germinal center formation and BCL6‐driven lymphomagenesis</article-title>. <source>Nat Immunol.</source><year>2019</year>;<volume>20</volume>(<issue>1</issue>):<fpage>86</fpage>‐<lpage>96</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41590-018-0273-1</pub-id>
<pub-id pub-id-type="pmid">30538335</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0020"><string-name><surname>Kanouni</surname><given-names>T</given-names></string-name>, <string-name><surname>Severin</surname><given-names>C</given-names></string-name>, <string-name><surname>Cho</surname><given-names>RW</given-names></string-name>, et al. <article-title>Discovery of CC‐90011: a potent and selective reversible inhibitor of lysine specific demethylase 1 (LSD1)</article-title>. <source>J Med Chem.</source><year>2020</year>;<volume>63</volume>(<issue>23</issue>):<fpage>14522</fpage>‐<lpage>14529</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00978</pub-id>
<pub-id pub-id-type="pmid">33034194</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0021"><string-name><surname>Aix</surname><given-names>SP</given-names></string-name>, <string-name><surname>Juan‐Vidal</surname><given-names>O</given-names></string-name>, <string-name><surname>Carcereny</surname><given-names>E</given-names></string-name>, et al. <article-title>50P A phase Ib study of CC‐90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first‐line (1L) extensive‐stage (ES) small cell lung cancer (SCLC): updated results</article-title>. <source>J Thorac Oncol.</source><year>2021</year>;<volume>16</volume>(<issue>4 suppl</issue>):<fpage>S722</fpage>‐<lpage>S723</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1556-0864(21)01892-X</pub-id>
</mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0022"><string-name><surname>Hollebecque</surname><given-names>A</given-names></string-name>, <string-name><surname>Salvagni</surname><given-names>S</given-names></string-name>, <string-name><surname>Plummer</surname><given-names>R</given-names></string-name>, et al. <article-title>Phase I study of lysine‐specific demethylase 1 inhibitor, CC‐90011, in patients with advanced solid tumors and relapsed/refractory non‐Hodgkin lymphoma</article-title>. <source>Clin Cancer Res.</source><year>2021</year>;<volume>27</volume>(<issue>2</issue>):<fpage>438</fpage>‐<lpage>446</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-2380</pub-id>
<pub-id pub-id-type="pmid">33046517</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0023"><string-name><surname>Cheson</surname><given-names>BD</given-names></string-name>, <string-name><surname>Fisher</surname><given-names>RI</given-names></string-name>, <string-name><surname>Barrington</surname><given-names>SF</given-names></string-name>, et al. <article-title>Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification</article-title>. <source>J Clin Oncol.</source><year>2014</year>;<volume>32</volume>(<issue>27</issue>):<fpage>3059</fpage>‐<lpage>3068</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2013.54.8800</pub-id>
<pub-id pub-id-type="pmid">25113753</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0024"><string-name><surname>Eisenhauer</surname><given-names>EA</given-names></string-name>, <string-name><surname>Therasse</surname><given-names>P</given-names></string-name>, <string-name><surname>Bogaerts</surname><given-names>J</given-names></string-name>, et al. <article-title>New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer.</source><year>2009</year>;<volume>45</volume>(<issue>2</issue>):<fpage>228</fpage>‐<lpage>247</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id>
<pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0025"><string-name><surname>Scher</surname><given-names>HI</given-names></string-name>, <string-name><surname>Morris</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Stadler</surname><given-names>WM</given-names></string-name>, et al. <article-title>Trial design and objectives for castration‐resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3</article-title>. <source>J Clin Oncol.</source><year>2016</year>;<volume>34</volume>(<issue>12</issue>):<fpage>1402</fpage>‐<lpage>1418</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2015.64.2702</pub-id>
<pub-id pub-id-type="pmid">26903579</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0026"><string-name><surname>Hollebecque</surname><given-names>A</given-names></string-name>, <string-name><surname>de Bono</surname><given-names>JS</given-names></string-name>, <string-name><surname>Salvagni</surname><given-names>S</given-names></string-name>, et al. <article-title>18O CC‐90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): updated results of a phase I study [abstract]</article-title>. <source>Ann Oncol.</source><year>2020</year>;<volume>31</volume>(<issue>suppl 1</issue>):<fpage>S6</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.annonc.2020.01.027</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0027"><string-name><surname>Gkolfinopoulos</surname><given-names>S</given-names></string-name>, <string-name><surname>Tsapakidis</surname><given-names>K</given-names></string-name>, <string-name><surname>Papadimitriou</surname><given-names>K</given-names></string-name>, <string-name><surname>Papamichael</surname><given-names>D</given-names></string-name>, <string-name><surname>Kountourakis</surname><given-names>P</given-names></string-name>. <article-title>Chromogranin A as a valid marker in oncology: clinical application or false hopes?</article-title><source>World J Methodol.</source><year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>9</fpage>‐<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.5662/wjm.v7.i1.9</pub-id>
<pub-id pub-id-type="pmid">28396845</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0028"><string-name><surname>Korse</surname><given-names>CM</given-names></string-name>, <string-name><surname>Taal</surname><given-names>BG</given-names></string-name>, <string-name><surname>Vincent</surname><given-names>A</given-names></string-name>, et al. <article-title>Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of chromogranin A, neuron specific enolase, progastrin‐releasing peptide and cytokeratin fragments</article-title>. <source>Eur J Cancer.</source><year>2012</year>;<volume>48</volume>(<issue>5</issue>):<fpage>662</fpage>‐<lpage>671</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2011.08.012</pub-id>
<pub-id pub-id-type="pmid">21945100</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0029"><string-name><surname>Fang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liao</surname><given-names>G</given-names></string-name>, <string-name><surname>Yu</surname><given-names>B</given-names></string-name>. <article-title>LSD1/KDM1A inhibitors in clinical trials: advances and prospects</article-title>. <source>J Hematol Oncol.</source><year>2019</year>;<volume>12</volume>(<issue>1</issue>):<fpage>129</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13045-019-0811-9</pub-id><pub-id pub-id-type="pmid">31801559</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0030"><string-name><surname>Maes</surname><given-names>T</given-names></string-name>, <string-name><surname>Mascaro</surname><given-names>C</given-names></string-name>, <string-name><surname>Tirapu</surname><given-names>I</given-names></string-name>, et al. <article-title>ORY‐1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia</article-title>. <source>Cancer Cell.</source><year>2018</year>;<volume>33</volume>(<issue>3</issue>):<fpage>495</fpage>‐<lpage>511.e12</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccell.2018.02.002</pub-id>
<pub-id pub-id-type="pmid">29502954</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0031"><string-name><surname>Salamero</surname><given-names>O</given-names></string-name>, <string-name><surname>Montesinos</surname><given-names>P</given-names></string-name>, <string-name><surname>Willekens</surname><given-names>C</given-names></string-name>, et al. <article-title>First‐in‐human phase I study of iadademstat (ORY‐1001): a first‐in‐class lysine‐specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia</article-title>. <source>J Clin Oncol.</source><year>2020</year>;<volume>38</volume>(<issue>36</issue>):<fpage>4260</fpage>‐<lpage>4273</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.19.03250</pub-id>
<pub-id pub-id-type="pmid">33052756</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0032"><string-name><surname>Bauer</surname><given-names>TM</given-names></string-name>, <string-name><surname>Besse</surname><given-names>B</given-names></string-name>, <string-name><surname>Martinez‐Marti</surname><given-names>A</given-names></string-name>, et al. <article-title>Phase I, open‐label, dose‐escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC</article-title>. <source>J Thorac Oncol.</source><year>2019</year>;<volume>14</volume>(<issue>10</issue>):<fpage>1828</fpage>‐<lpage>1838</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jtho.2019.06.021</pub-id>
<pub-id pub-id-type="pmid">31260835</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0033"><string-name><surname>Sprussel</surname><given-names>A</given-names></string-name>, <string-name><surname>Schulte</surname><given-names>JH</given-names></string-name>, <string-name><surname>Weber</surname><given-names>S</given-names></string-name>, et al. <article-title>Lysine‐specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation</article-title>. <source>Leukemia.</source><year>2012</year>;<volume>26</volume>(<issue>9</issue>):<fpage>2039</fpage>‐<lpage>2051</lpage>. doi:<pub-id pub-id-type="doi">10.1038/leu.2012.157</pub-id>
<pub-id pub-id-type="pmid">22699452</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="miscellaneous" id="cncr34366-cit-0034"><collab collab-type="authors">Celgene Corporation</collab>
. <article-title>A Safety and Efficacy Study of CC‐90011 in Combination With Nivolumab in Subjects With Advanced Cancers [ClinicalTrials.gov identifier NCT04350463]</article-title>. Celgene Corporation; <year>2022</year>.</mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="miscellaneous" id="cncr34366-cit-0035"><article-title>Celgene Corporation. A Study of CC‐90011 and Comparators in Participants With Prostate Cancer [ClinicalTrials.gov identifier: NCT04628988]</article-title>. Celgene Corporation; <year>2022</year>.</mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="miscellaneous" id="cncr34366-cit-0036"><collab collab-type="authors">Celgene Corporation</collab>
. <article-title>A Safety, Tolerability and Preliminary Efficacy Study of CC‐90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment‐Naive Participants Not Eligible for Intensive Therapy [ClinicalTrials.gov identifier: NCT0478848]</article-title>. Celgene Corporation; <year>2022</year>.</mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0037"><string-name><surname>Hollebecque</surname><given-names>A</given-names></string-name>, <string-name><surname>de Bono</surname><given-names>J</given-names></string-name>, <string-name><surname>Plummer</surname><given-names>R</given-names></string-name>, et al. <article-title>Phase I study of CC‐90011 in patients with advanced solid tumors and relapsed/refractory non‐Hodgkin lymphoma (R/R NHL)</article-title>. <source>Ann Oncol.</source><year>2019</year>;<volume>30</volume>(<issue>suppl 1</issue>):<fpage>I4</fpage>.</mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0038"><string-name><surname>Di Giacinto</surname><given-names>P</given-names></string-name>, <string-name><surname>Rota</surname><given-names>F</given-names></string-name>, <string-name><surname>Rizza</surname><given-names>L</given-names></string-name>, et al. <article-title>Chromogranin A: from laboratory to clinical aspects of patients with neuroendocrine tumors</article-title>. <source>Int J Endocrinol.</source><year>2018</year>;<volume>2018</volume>:<fpage>8126087</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2018/8126087</pub-id><pub-id pub-id-type="pmid">30057604</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0039"><string-name><surname>Hollebecque</surname><given-names>A</given-names></string-name>, <string-name><surname>de Bono</surname><given-names>JS</given-names></string-name>, <string-name><surname>Salvagni</surname><given-names>S</given-names></string-name>, et al. <article-title>7O Updated results from phase 1 study of CC‐90011 in patients (Pts) with solid tumors, including neuroendocrine neoplasms (NENs), and relapsed/refractory non‐Hodgkin lymphoma. (R/R NHL) [abstract]</article-title>. <source>Ann Oncol</source>. <year>2021</year>;<volume>32</volume>(<issue>suppl 1</issue>):S4.</mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0040"><string-name><surname>Kloppel</surname><given-names>G</given-names></string-name>. <article-title>Neuroendocrine neoplasms: dichotomy, origin and classifications</article-title>. <source>Visc Med.</source><year>2017</year>;<volume>33</volume>(<issue>5</issue>):<fpage>324</fpage>‐<lpage>330</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000481390</pub-id>
<pub-id pub-id-type="pmid">29177160</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0041"><string-name><surname>Kulke</surname><given-names>MH</given-names></string-name>, <string-name><surname>Lenz</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Meropol</surname><given-names>NJ</given-names></string-name>, et al. <article-title>Activity of sunitinib in patients with advanced neuroendocrine tumors</article-title>. <source>J Clin Oncol.</source><year>2008</year>;<volume>26</volume>(<issue>20</issue>):<fpage>3403</fpage>‐<lpage>3410</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2007.15.9020</pub-id>
<pub-id pub-id-type="pmid">18612155</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0042"><string-name><surname>Simoneaux</surname><given-names>R</given-names></string-name>. <article-title>A look at the increasing incidence of neuroendocrine tumors</article-title>. <source>Oncol Times.</source><year>2020</year>;<volume>42</volume>(<issue>6</issue>):<fpage>1</fpage>‐<lpage>4</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.COT.0000658812.91924.c3</pub-id>
</mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0043"><string-name><surname>Dasari</surname><given-names>A</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Halperin</surname><given-names>D</given-names></string-name>, et al. <article-title>Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States</article-title>. <source>JAMA Oncol.</source><year>2017</year>;<volume>3</volume>(<issue>10</issue>):<fpage>1335</fpage>‐<lpage>1342</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaoncol.2017.0589</pub-id>
<pub-id pub-id-type="pmid">28448665</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0044"><string-name><surname>Hallet</surname><given-names>J</given-names></string-name>, <string-name><surname>Law</surname><given-names>CH</given-names></string-name>, <string-name><surname>Cukier</surname><given-names>M</given-names></string-name>, <string-name><surname>Saskin</surname><given-names>R</given-names></string-name>, <string-name><surname>Liu</surname><given-names>N</given-names></string-name>, <string-name><surname>Singh</surname><given-names>S</given-names></string-name>. <article-title>Exploring the rising incidence of neuroendocrine tumors: a population‐based analysis of epidemiology, metastatic presentation, and outcomes</article-title>. <source>Cancer.</source><year>2015</year>;<volume>121</volume>(<issue>4</issue>):<fpage>589</fpage>‐<lpage>597</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.29099</pub-id>
<pub-id pub-id-type="pmid">25312765</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0045"><string-name><surname>Tsoli</surname><given-names>M</given-names></string-name>, <string-name><surname>Chatzellis</surname><given-names>E</given-names></string-name>, <string-name><surname>Koumarianou</surname><given-names>A</given-names></string-name>, <string-name><surname>Kolomodi</surname><given-names>D</given-names></string-name>, <string-name><surname>Kaltsas</surname><given-names>G</given-names></string-name>. <article-title>Current best practice in the management of neuroendocrine tumors</article-title>. <source>Ther Adv Endocrinol Metab.</source><year>2019</year>;<volume>10</volume>:<fpage>2042018818804698</fpage>. doi:<pub-id pub-id-type="doi">10.1177/2042018818804698</pub-id><pub-id pub-id-type="pmid">30800264</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0046"><string-name><surname>Peri</surname><given-names>M</given-names></string-name>, <string-name><surname>Fazio</surname><given-names>N</given-names></string-name>. <article-title>Clinical evaluation of everolimus in the treatment of neuroendocrine tumors of the lung: patient selection and special considerations. A systematic and critical review of the literature</article-title>. <source>Lung Cancer (Auckl).</source><year>2020</year>;<volume>11</volume>:<fpage>41</fpage>‐<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.2147/LCTT.S249928</pub-id>
<pub-id pub-id-type="pmid">32753993</pub-id></mixed-citation>
              </ref>
              <ref id="cncr34366-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="cncr34366-cit-0047"><string-name><surname>Herrera‐Martinez</surname><given-names>AD</given-names></string-name>, <string-name><surname>Hofland</surname><given-names>J</given-names></string-name>, <string-name><surname>Hofland</surname><given-names>LJ</given-names></string-name>, et al. <article-title>Targeted systemic treatment of neuroendocrine tumors: current options and future perspectives</article-title>. <source>Drugs.</source><year>2019</year>;<volume>79</volume>(<issue>1</issue>):<fpage>21</fpage>‐<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40265-018-1033-0</pub-id>
<pub-id pub-id-type="pmid">30560479</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
